Pubblicazioni scientifiche

Mattioli S.; Verbeek J.; Mattei S.; Curti S., Effectiveness of preventive interventions and randomised controlled trials in occupational health: An overview of the last five decades, «LA MEDICINA DEL LAVORO», 2021, 112, pp. 258 - 263 [Articolo in rivista]

Brennenstuhl H.; Nashawi M.; Schroter J.; Baronio F.; Beedgen L.; Gleich F.; Jeltsch K.; von Landenberg C.; Martini S.; Simon A.; Thiel C.; Tsiakas K.; Opladen T.; Kolker S.; Hoffmann G.F.; Haas D.; Garcia-Cazorla A.; Dionisi-Vici C.; Martinelli D.; Kozich V.; Scarpa M., Phenotypic diversity, disease progression, and pathogenicity of MVK missense variants in mevalonic aciduria, «JOURNAL OF INHERITED METABOLIC DISEASE», 2021, 44, pp. 1272 - 1287 [Articolo in rivista] Open Access

Vannini A.; Leoni V.; Sanapo M.; Gianni T.; Giordani G.; Gatta V.; Barboni C.; Zaghini A.; Campadelli-fiume G., Immunotherapeutic efficacy of retargeted ohsvs designed for propagation in an ad hoc cell line, «CANCERS», 2021, 13, pp. 1 - 22 [Articolo in rivista] Open Access

Tomassi S.; D'Amore V.M.; Di Leva F.S.; Vannini A.; Quilici G.; Weinmuller M.; Reichart F.; Amato J.; Romano B.; Izzo A.A.; Di Maro S.; Novellino E.; Musco G.; Gianni T.; Kessler H.; Marinelli L., Halting the Spread of Herpes Simplex Virus-1: The Discovery of an Effective Dual αvβ6/αvβ8 Integrin Ligand, «JOURNAL OF MEDICINAL CHEMISTRY», 2021, 64, pp. 6972 - 6984 [Articolo in rivista] Open Access

Vannini A.; Parenti F.; Bressanin D.; Barboni C.; Zaghini A.; Campadelli-Fiume G.; Gianni T., Towards a precision medicine approach and in situ vaccination against prostate cancer by psma-retargeted ohsv, «VIRUSES», 2021, 13, pp. 1 - 22 [Articolo in rivista] Open Access

Gianni T.; Leoni V.; Sanapo M.; Parenti F.; Bressanin D.; Barboni C.; Zaghini A.; Campadelli-Fiume G.; Vannini A., Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV, «VIRUSES», 2021, 13, pp. 1 - 18 [Articolo in rivista] Open Access

Ricci, A. D.; Rizzo, A.; Brandi, G., In Regard to “A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)”, «THE ONCOLOGIST», 2021, 26, pp. e902 - e902 [Replica/breve intervento (e simili)]

Brandi G.; Frega G.; Rizzo A., Second-line FOLFOX chemotherapy for advanced biliary tract cancer, «THE LANCET ONCOLOGY», 2021, 22, pp. e285 - e285 [Replica/breve intervento (e simili)]

Rizzo A.; Brandi G., BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 483 - 485 [Replica/breve intervento (e simili)]

Rizzo A.; Ricci A.D.; Brandi G., Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer, «HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL», 2021, 20, pp. 506 - 507 [Replica/breve intervento (e simili)]

Rizzo A.; Brandi G., TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, pp. 1 - 2 [Replica/breve intervento (e simili)] Open Access

Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G., Nivolumab: an investigational agent for the treatment of biliary tract cancer, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 30, pp. 325 - 332 [Articolo in rivista]

Rizzo A.; Brandi G., First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”, «CANCER TREATMENT AND RESEARCH COMMUNICATIONS», 2021, 27, pp. 1 - 7 [Articolo in rivista] Open Access

Rizzo A.; Ricci A.D.; Brandi G., Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2021, 6, pp. 225 - 227 [Articolo in rivista]

Rizzo A.; Ricci A.D.; Frega G.; Di Federico A.; Brandi G., FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue, «EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY», 2021, 15, pp. 567 - 574 [Articolo in rivista]

Munoz-Martinez S.; Sapena V.; Forner A.; Nault J.-C.; Sapisochin G.; Rimassa L.; Sangro B.; Bruix J.; Sanduzzi-Zamparelli M.; Holowko W.; El Kassas M.; Mocan T.; Bouattour M.; Merle P.; Hoogwater F.J.H.; Alqahtani S.A.; Reeves H.L.; Pinato D.J.; Giorgakis E.; Meyer T.; Villadsen G.E.; Wege H.; Salati M.; Minguez B.; Di Costanzo G.G.; Roderburg C.; Tacke F.; Varela M.; Galle P.R.; Alvares-da-Silva M.R.; Trojan J.; Bridgewater J.; Cabibbo G.; Toso C.; Lachenmayer A.; Casadei-Gardini A.; Toyoda H.; Ludde T.; Villani R.; Matilla Pena A.M.; Guedes Leal C.R.; Ronzoni M.; Delgado M.; Perello C.; Pascual S.; Lledo J.L.; Argemi J.; Basu B.; da Fonseca L.; Acevedo J.; Siebenhuner A.R.; Braconi C.; Meyers B.M.; Granito A.; Sala M.; Rodriguez-Lope C.; Blaise L.; Romero-Gomez M.; Pinero F.; Gomez D.; Mello V.; Pinheiro Alves R.C.; Franca A.; Branco F.; Brandi G.; Pereira G.; Coll S.; Guarino M.; Benitez C.; Anders M.M.; Bandi J.C.; Vergara M.; Calvo M.; Peck-Radosavljevic M.; Garcia-Juarez I.; Car, Assessing the impact of COVID-19 on liver cancer management (CERO-19), «JHEP REPORTS», 2021, 3, pp. 1 - 9 [Articolo in rivista] Open Access

Rizzo A.; Ricci A.D.; Bonucci C.; Tober N.; Palloni A.; Frega G.; Brandi G., Experimental HER2- targeted therapies for biliary tract cancer, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 30, pp. 389 - 399 [Articolo in rivista]

Rizzo A.; Ricci A.D.; Brandi G., Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2021, 30, pp. 343 - 350 [Articolo in rivista]

Rizzo A.; Ricci A.D.; Brandi G., Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2021, 6, pp. 217 - 224 [Articolo in rivista]

Kudo M.; Galle P.R.; Brandi G.; Kang Y.-K.; Yen C.-J.; Finn R.S.; Llovet J.M.; Assenat E.; Merle P.; Chan S.L.; Palmer D.H.; Ikeda M.; Yamashita T.; Vogel A.; Huang Y.-H.; Abada P.B.; Yoshikawa R.; Shinozaki K.; Wang C.; Widau R.C.; Zhu A.X., Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2, «JHEP REPORTS», 2021, 3, pp. 1 - 12 [Articolo in rivista] Open Access